Jeri Kim

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Electronic address
    EBioMedicine 7:85-93. 2016
  2. ncbi request reprint 5α-reductase inhibitors for prostate-cancer prevention
    Jeri Kim
    University of Texas M D Anderson Cancer Center, Houston, TX
    N Engl J Med 365:2340. 2011
  3. ncbi request reprint Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Box 427, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:21-6. 2003
  4. pmc Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer
    Dimitra Tsavachidou
    Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 101:306-20. 2009
  5. pmc Arachidonic acid metabolism in human prostate cancer
    Peiying Yang
    Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Oncol 41:1495-503. 2012
  6. pmc Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
    Sue Hwa Lin
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:3729-36. 2008
  7. ncbi request reprint Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7904-10. 2005
  8. ncbi request reprint Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:6189-98. 2005
  9. pmc Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention
    Jin Li
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e28840. 2011
  10. pmc Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance
    John W Davis
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 118:68-76. 2016

Research Grants

Detail Information

Publications40

  1. pmc Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Electronic address
    EBioMedicine 7:85-93. 2016
    ..However, an apparent increase in high-grade disease was also observed among men randomized to finasteride. We aimed to determine why and hypothesized that there is a grade-dependent response to finasteride...
  2. ncbi request reprint 5α-reductase inhibitors for prostate-cancer prevention
    Jeri Kim
    University of Texas M D Anderson Cancer Center, Houston, TX
    N Engl J Med 365:2340. 2011
    ..7% with finasteride . . ...
  3. ncbi request reprint Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Box 427, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:21-6. 2003
    ..8 to 17.1 months), with a 15.9-month median survival for 3 patients with poor performance status and visceral metastases. Further clinical investigation of the biological effect of IL-2 in urothelial carcinoma may be warranted...
  4. pmc Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer
    Dimitra Tsavachidou
    Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 101:306-20. 2009
    ....
  5. pmc Arachidonic acid metabolism in human prostate cancer
    Peiying Yang
    Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Oncol 41:1495-503. 2012
    ..0.010 ng/mg protein, respectively; p=0.019). Our results suggest that LOX metabolites such as 12-HETE are critical in prostate cancer progression and that the LOX pathway may be a target for treating and preventing prostate cancer...
  6. pmc Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
    Sue Hwa Lin
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:3729-36. 2008
    ..We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples...
  7. ncbi request reprint Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7904-10. 2005
    ..We assessed the rate of bone marrow failure in patients with prostate cancer who had received a dose of strontium-89...
  8. ncbi request reprint Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:6189-98. 2005
    ....
  9. pmc Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention
    Jin Li
    Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e28840. 2011
    ..The different expression levels of 5α-reductase isoenzymes may confer response or resistance to 5α-reductase inhibitors and thus may have importance in prostate cancer prevention...
  10. pmc Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance
    John W Davis
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 118:68-76. 2016
    ..To determine the frequency of disease reclassification and to identify clinicopathological variables associated with it in patients with favourable-risk prostate cancer undergoing active surveillance (AS)...
  11. doi request reprint Molecular profiles of finasteride effects on prostate carcinogenesis
    Jin Li
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1374, Houston, Texas 77030, USA
    Cancer Prev Res (Phila) 2:518-24. 2009
    ..Ongoing studies using a systems biology approach in a preoperative prostate cancer setting are testing this hypothesis toward developing more-rational clinical interventions...
  12. ncbi request reprint Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:342-8. 2003
    ..Furthermore, the complicated dosing schedule and toxic effects of the regimen precluded its routine use in the treatment of urothelial carcinoma...
  13. pmc Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia
    Vemparala Subbarayan
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 7:280-93. 2005
    ..These results suggest that feedback mechanisms may contribute to the loss of 15-LOX-2 pathway components, which coincide with an increase in PPAR-gamma in many epithelial cancers...
  14. ncbi request reprint Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells
    Matthew Galfione
    Department of Molecular Pathology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Protein Expr Purif 28:252-8. 2003
    ..This 16-kDa PRL expressed in Sf9 cells is a useful reagent for functional studies and for the purification and identification of its receptor...
  15. ncbi request reprint Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer
    Jeri Kim
    Department of Genitourinary Medical Oncology, University of Massachusetts Medical School, Lazare Research Building, Room 504, 364 Plantation Street, Worcester, MA 01605 2324, USA
    Cancer Epidemiol Biomarkers Prev 14:1697-702. 2005
    ..To determine the effects of selenium and vitamin E in blood and prostate tissue, we undertook a preoperative feasibility study complementary to the currently ongoing Selenium and Vitamin E Cancer Prevention Trial...
  16. doi request reprint Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci
    John W Davis
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    BJU Int 105:1386-91. 2010
    ....
  17. pmc Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer
    Christopher J Logothetis
    Departments of 1Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Discov 3:849-61. 2013
    ..We use this model to discuss how integrating clinical and basic understanding of prostate cancer will lead to better implementation of molecularly targeted therapeutics and improve patient survival. ..
  18. pmc Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance
    Xiang Shu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 37:965-71. 2016
    ..016 in phase III). In summary, rs752822 and rs2735839 may assist in risk-stratifying GS 7 patients and predict prostate cancer reclassification. The significant associations were independent from GS, T stage and PSA levels at baseline. ..
  19. ncbi request reprint Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies
    Shifeng Mao
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Prostate 67:1677-85. 2007
    ....
  20. pmc Platinum-based chemotherapy for variant castrate-resistant prostate cancer
    Ana M Aparicio
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 3721, USA
    Clin Cancer Res 19:3621-30. 2013
    ....
  21. pmc Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer
    Huakang Tu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 6:41988-96. 2015
    ..96-2.54; P = 0.07). In summary, our results suggested that low mtDNAcn in peripheral blood leukocytes was associated with aggressive PCa at diagnosis and might further predict poor progression-free survival among localized PCa patients. ..
  22. pmc Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    BJU Int 111:934-40. 2013
    ..These findings raise the spectre of over-treatment for a group of men likely to be affected by treatment side-effects...
  23. pmc Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance
    Patricia A Parker
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 117:469-77. 2016
    ..To evaluate prospectively the associations between illness uncertainty, anxiety, fear of progression and general and disease-specific quality of life (QoL) in men with favourable-risk prostate cancer undergoing active surveillance (AS)...
  24. ncbi request reprint Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity
    Thomas R Salas
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 279:19191-200. 2004
    ....
  25. ncbi request reprint Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, Division of Medicine, The University of Texas M D Anderson Cancer Center, 1515 M D Anderson Boulevard, Houston, TX 77030, USA
    Lung Cancer 37:17-27. 2002
    ..Taken together, these data indicate that trastuzumab warrants further investigation in a clinical study in selected patients with NSCLC...
  26. ncbi request reprint Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
    Spyridon P Basourakos
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
    Curr Med Chem . 2016
    ....
  27. ncbi request reprint Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells
    Vemparala Subbarayan
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Unit 236, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 13:1710-6. 2004
    ..These findings have important implications for the development of PPAR-gamma-targeting agents that prevent or treat prostate cancer and spare normal prostate cells...
  28. ncbi request reprint Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
    Christos N Papandreou
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 0427, Houston, TX 77030, USA
    J Clin Oncol 22:2108-21. 2004
    ....
  29. pmc Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic
    Lydia T Madsen
    From the Departments of Genitourinary Medical Oncology, Radiation Oncology, Urology, and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Natl Compr Canc Netw 12:993-8. 2014
    ..Clinical trial enrollment in the MPCC was substantially higher than that seen nationally in adult patients with cancer, and enrollment rates increased after the introduction of a clinical trial initiative...
  30. pmc Physician variation in management of low-risk prostate cancer: a population-based cohort study
    Karen E Hoffman
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
    JAMA Intern Med 174:1450-9. 2014
    ..The impact of physicians on the management approach is uncertain...
  31. doi request reprint The implications of ageing and life expectancy in prostate cancer treatment
    Sarathi Kalra
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Urol 13:289-95. 2016
    ....
  32. ncbi request reprint Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow
    Funda Vakar-Lopez
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pathol 203:688-95. 2004
    ..These observations indicate that MDA-BF-1 is up-regulated in metastatic PCa and raise the interesting possibility that MDA-BF-1 may play a role in the metastasis and progression of PCa, particularly in bone...
  33. ncbi request reprint Antitumor activity of the 16-kDa prolactin fragment in prostate cancer
    Jeri Kim
    Departments of Genitourinary Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 63:386-93. 2003
    ..These results suggest that the 16-kDa PRL has potential as a treatment agent in prostate cancer...
  34. pmc The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients
    Yonggang He
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Clin Cancer Res 20:5133-9. 2014
    ..Gleason score (GS) 7 prostate cancer is a heterogeneous disease with different clinical behavior. We sought to identify genetic biomarkers that may predict the aggressiveness of GS 7 diseases...
  35. ncbi request reprint 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway
    Sok Hyong Lee
    Department of Immunology, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 65:7984-92. 2005
    ..Thus, 16-kDa PRL inhibits the p38 MAPK/Stat1/IRF-1 pathway to attenuate iNOS/NO production in endothelial cells...
  36. ncbi request reprint Fingerprinting the circulating repertoire of antibodies from cancer patients
    Paul J Mintz
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Biotechnol 21:57-63. 2003
    ..Exploiting the differential humoral response to cancer through such an approach may identify molecular markers and targets for diagnostic and therapeutic intervention...
  37. pmc Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments
    Deborah J Del Junco
    Department of Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA
    J Urol 185:2137-42. 2011
    ..Thus, we determined whether United States Air Force prostate cancer incidence rates increased thereafter and how these tumors segregate into low and intermediate/high risk categories. We also identified treatment choices...
  38. pmc Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells
    Chien Jui Cheng
    Department of Pathology, Taipei Medical University and Hospital, Taipei, Taiwan
    Mol Cancer Res 5:675-84. 2007
    ..We speculate that nuclear localization of ErbB-3 may aid prostate cancer cell survival during androgen ablation and progression of prostate cancer in bone...
  39. ncbi request reprint High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Anticancer Res 24:2897-903. 2004
    ..To assess the activity of docetaxel in combination with hormonal therapy in preclinical models of prostate cancer...
  40. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....

Research Grants1

  1. Differential Gene Expression Induced by Antioxidants
    Jeri Kim; Fiscal Year: 2004
    ..Once characterized, these SBs will widen the scope and enhance the feasibility of prostate cancer trials, creating broader opportunities for advances toward successful prevention, effective treatment, and eventual cure. ..